Mariel del Rio-Cadorette, MD
Infectious Disease · Fall River, MANPI 1750328290
Payments from drug & device makers
Across 47 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$174
- Viiv Healthcare Company$108
- Novartis$83
- Merck$69
- AbbVie$53
- Paratek Pharmaceuticals, Inc.$51
- plus $317 from 13 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$77691%
- Education$819%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 8 | $174 |
| Viiv Healthcare Company | 5 | $108 |
| Novartis | 5 | $83 |
| Merck | 5 | $69 |
| AbbVie(2 entities) | 4 | $53 |
| Paratek Pharmaceuticals, Inc. | 1 | $51 |
| Novo Nordisk | 3 | $45 |
| Johnson & Johnson(2 entities) | 2 | $39 |
| Indivior Inc. | 2 | $35 |
| Pfizer | 2 | $30 |
| Astellas Pharma US Inc | 1 | $30 |
| Lilly USA, LLC | 2 | $28 |
| AstraZeneca | 1 | $20 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Alkermes, Inc. | 1 | $11 |
How this compares
$857 in reported general payments places this provider in the 65th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fosfomycin Tromethamine | 204 | $46,044 |
| Methenamine Hippurate | 64 | $2,946 |
| Cefpodoxime Proxetil | 23 | $2,196 |
| Vancomycin Hcl | 12 | $1,872 |
| Cephalexin | 34 | $1,078 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 27 | $545 |
| Minocycline Hcl | 23 | $499 |
| Doxycycline Hyclate | 17 | $348 |
| Cefdinir | 16 | $305 |
| CefuroximeCefuroxime Axetil | 14 | $261 |
| Amoxicillin | 39 | $168 |
| Clotrimazole | 14 | $160 |
| Fluconazole | 11 | $122 |
| Ciprofloxacin Hcl | 11 | $55 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $27 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Fall River
- Dan BarouchBoston$35.8M
- Shahin LockmanBoston$7.4M
- Francisco MartyBoston$6.2M
- Stephen WalshBoston$5.4M
- Sophia KooBoston$4.9M
- Jennifer WangWorcester$2.7M
- David SnydmanBoston$2.6M
- Claudia MartorellSpringfield$2.4M
- Yoav GolanBoston$1.8M
- Robert FinbergWorcester$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.